Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models

Date

23 Nov 2019

Session

Poster display session

Topics

Clinical Research

Tumour Site

Presenters

Rachel Sparks

Citation

Annals of Oncology (2019) 30 (suppl_9): ix22-ix29. 10.1093/annonc/mdz420

Authors

R. Sparks1, S. Rolland2, S. Klinz1, F. Meyer-Losic2, J. Nakhle2, R. Delille2, M. Hillairet de Boisferonc3

Author affiliations

  • 1 Oncology, Ipsen Bioscience, 02142 - Cambridge/US
  • 2 Oncology, Ipsen Innovation, 91140 - Les Ulis/FR
  • 3 Oncology, Oncodesign, 21000 - Dijon/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 73P

Background

Cabozantinib (C), a tyrosine kinase inhibitor against VEGFR2, RET, MET and Axl, has demonstrated clinical activity in RCC and 2L HCC, and has been shown to promote an immune-permissive environment. C is being investigated in clinical trials in combination with immune checkpoint inhibitors (ICI). This preclinical study aimed to determine systemic cytokine profile changes induced by the combination of C + αPD1 and assess cooperativity in anti-tumoral effects.

Methods

Syngeneic colon (CT26, Colon38) and bladder (MBT2) tumour models were established in BALB/C, C57Bl6 or C3H/HEJ mice. C (10 or 30 mg/kg po qd) and αPD1 (10 mg/kg ip 2x weekly) were administered either simultaneously for up to 30 days or with a 14-day delay for αPD1, and serum was collected.

Results

After 30 days' coadministration of C (30 mg/kg) and αPD1, serum cytokines and chemokines (VEGFA, IL3, GM-CSF, MIP1beta, IL17, CCL5, IFNγ, IL10, IL5) were elevated with a median of 72x (range 39–1207x), as compared to 30-days' single administration of αPD1 or C with a median of 3.7x (1.4–135x) and 1.0x (0.5–1.9x), respectively, relative to vehicle-treated animals. Delayed treatment with αPD1 did not result in the same increase in analyte levels as coadministration (median of 1.74x [1–9.9x]). For anti-tumour efficacies, two C doses were explored in CT26 (T/C10/30 67/38% - tumour growth inhibition T/C ratios at 10 or 30 mg/kg), MBT2 (T/C10/30 37/14%) and Colon38 (T/C10/30 21/12%) models. C at 30 mg/kg led to strong anti-tumour efficacy in MBT2 and Colon38, limiting any ICI combinatorial impact to the post-treatment tumour expansion. For CT26 (30 mg/kg) and MBT2 (10 mg/kg), simultaneous dosing of C and αPD1 showed greater anti-tumour effects than single agents despite only limited effects of αPD1 alone. C + αPD1 more than doubled the treatment-specific time that tumours required to reach 1000mm3 compared to C alone.

Conclusions

The results indicate that simultaneous treatment of C + αPD1 leads to strong systemic increases in key cytokines and chemokines and can result in robust anti-tumour efficacy. Our results support the clinical exploration of C + ICI combinations and the potential of this TKI for use in further clinical settings.

Clinical trial identification

Editorial acknowledgement

Isabelle Kaufmann, PhD of Oxford PharmaGenesis, Oxford, UK for provided medical writing support, which was sponsored by Ipsen, Abingdon, UK.

Legal entity responsible for the study

Ipsen.

Funding

Ipsen.

Disclosure

R. Sparks: Full / Part-time employment: Ipsen. S. Rolland: Full / Part-time employment: Ipsen. S. Klinz: Full / Part-time employment: Ipsen. F. Meyer-Losic: Full / Part-time employment: Ipsen. J. Nakhle: Full / Part-time employment: Ipsen. R. Delille: Full / Part-time employment: Ipsen. M. Hillairet de Boisferonc: Research grant / Funding (institution), Contractual obligation: Ipsen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.